Novartis Sues Biocon For Patent Infringment Of Galvus Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
Biocon has been sued in Delhi High Court for patent infringement of Novartis’ Galvus for diabetes after the Indian biotech set plans to launch a generic of vildagliptin.